<?xml version="1.0" encoding="UTF-8" standalone="no"?><rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:admin="http://webns.net/mvcb/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/">

<channel rdf:about="http://www.bmj.com">
<title>Latest headlines from BMJ</title>
<link>http://www.bmj.com</link>
<description></description>
<prism:eIssn>1756-1833</prism:eIssn>
<prism:publicationName>BMJ</prism:publicationName>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.bmj.com/content/393/bmj-2026-688241.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/393/bmj-2026-308194.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/393/bmj-2026-491185.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/393/bmj-2026-803029.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/393/bmj-2025-088686.short?rss=1"/>
  <rdf:li rdf:resource="http://www.bmj.com/content/393/bmj-2026-715244.short?rss=1"/>
 </rdf:Seq>
</items>
<image rdf:resource="http://www.bmj.com/icons/site/logo.bmj.gif"/>
<xhtml:meta content="noindex" name="robots" xmlns:xhtml="http://www.w3.org/1999/xhtml"/></channel>
<image rdf:about="http://www.bmj.com/icons/site/logo.bmj.gif">
<title>BMJ</title>
<url>http://www.bmj.com/icons/site/logo.bmj.gif</url>
<link>http://www.bmj.com</link>
</image>
<item rdf:about="http://www.bmj.com/content/393/bmj-2026-688241.short?rss=1">
<title><![CDATA[Doctors face ban on &#x201C;political&#x201D; badges at work and wearing uniforms at protests, says official antisemitism review]]></title>
<link>http://www.bmj.com/content/393/bmj-2026-688241.short?rss=1</link>
<description><![CDATA[Doctors could be told to stop wearing political badges at work and not to attend political protests in work uniforms, after a national review.Strengthened official guidance on uniform and workwear for NHS staff is expected after a government commissioned review on tackling antisemitism and other forms of racism across the NHS.1However, doctors' leaders labelled some of the proposals as “deeply concerning.”They said having a “blanket ban” on all symbols being worn as a step too far and there are questions over who decides what is “political.”The review, carried out by the Labour peer and UK government adviser on antisemitism John Mann, was commissioned after an attack at Heaton Park Synagogue in Manchester in October 2025 and reports of doctors being struck off the medical register because of antisemitic comments.2Mann heard from Jewish people who said they experienced “routine ostracism” in the NHS.Jewish staff were also the only religious group in...]]></description>
<dc:creator><![CDATA[Adrian O'Dowd]]></dc:creator>
<dc:date>2026-06-05T07:11:11-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-688241</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-688241</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Doctors face ban on &#x201C;political&#x201D; badges at work and wearing uniforms at protests, says official antisemitism review]]></dc:title>
<prism:publicationDate>2026-06-05</prism:publicationDate>
<prism:section>News</prism:section>
<prism:volume>393</prism:volume>
<prism:issueIdentifier>jun05_13</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/393/bmj-2026-308194.short?rss=1">
<title><![CDATA[Childcare problems are compounded for dual doctor couples]]></title>
<link>http://www.bmj.com/content/393/bmj-2026-308194.short?rss=1</link>
<description><![CDATA[McNally correctly identifies that many of the challenges affecting parents who are doctors are compounded for trainees with frequent rotations and often long commutes.1 Being a dual doctor couple, which has become increasingly common, further compounds the problem. The degree of influence that trainees have over their rotations varies considerably across grade, region, and training programme. We started a family during higher specialty training, but there are many parents in foundation or early specialty training who are even more vulnerable to these problems, with shorter rotations and even less agency. Most trusts lack an on-site nursery, which is of limited use when both parents are working in different places. Our friends and colleagues who rely on family might seem to have a better deal, but these arrangements often strain personal relationships and can be vulnerable to changes of health or circumstance.2Less than full time (LTFT) working has allowed my wife...]]></description>
<dc:creator><![CDATA[George C Greenlees]]></dc:creator>
<dc:date>2026-06-05T06:56:08-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-308194</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-308194</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Childcare problems are compounded for dual doctor couples]]></dc:title>
<prism:publicationDate>2026-06-05</prism:publicationDate>
<prism:section>Letters</prism:section>
<prism:subsection1>Letter</prism:subsection1>
<prism:volume>393</prism:volume>
<prism:issueIdentifier>jun05_12</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/393/bmj-2026-491185.short?rss=1">
<title><![CDATA[Eric Edwards]]></title>
<link>http://www.bmj.com/content/393/bmj-2026-491185.short?rss=1</link>
<description><![CDATA[bmj;393/jun05_11/e491185/VS1F1vs1Eric was born in Liverpool in 1925, was educated at Liverpool College, and went on to Liverpool University to study medicine.He qualified as a urologist and started his career at Sefton General, where he met his wife, Rosemary, who was working there as a physiotherapist. Most of his career was spent at the Manchester Royal Infirmary, where he became head of urology surgery.Eric was very involved in kidney research, and he spent his early career in the US at the Mayo Clinic, studying the artificial kidney. On his return to the UK, he developed and performed the first cadaver transplant. He was a leading force in Kidney Research Northwest and much involved in raising funds through the rugby sevens team. This was recognised by the Queen, and he attended one of her garden parties in the late 1970s.Eric became chair of the British Association of Urological Surgeons and was also...]]></description>
<dc:creator><![CDATA[Catherine McPherson]]></dc:creator>
<dc:date>2026-06-05T05:36:08-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-491185</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-491185</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Eric Edwards]]></dc:title>
<prism:publicationDate>2026-06-05</prism:publicationDate>
<prism:section>Obituaries</prism:section>
<prism:subsection1>Obituary</prism:subsection1>
<prism:volume>393</prism:volume>
<prism:issueIdentifier>jun05_11</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/393/bmj-2026-803029.short?rss=1">
<title><![CDATA[Ovarian cancer: What is the new drug approved for the NHS in England?]]></title>
<link>http://www.bmj.com/content/393/bmj-2026-803029.short?rss=1</link>
<description><![CDATA[A new drug to treat resistant ovarian cancer, and the first to be approved in over two decades, has been approved for patients in the NHS in England.What is the new drug?Mirvetuximab soravtansine (marketed as Elahere), developed by AbbVie, is an advanced, targeted treatment that combines a “homing” antibody with a cancer destroying drug.Often described by scientists as a “biological missile” or “trojan horse” therapy, the drug is already available in the US and Europe.It costs £4950 per 100 mg vial at list prices, excluding VAT.1 However, for the health service it is being made available subject to a confidential commercial arrangement between AbbVie and NHS England.How does it work?In contrast to chemotherapy, it uses a targeted therapy that seeks out a specific protein found on the surface of cancer cells called folate receptor alpha (FRα) and delivers a molecule that destroys the cancer cell from within.The drug is given...]]></description>
<dc:creator><![CDATA[Gareth Iacobucci]]></dc:creator>
<dc:date>2026-06-05T01:26:15-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-803029</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-803029</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:subject><![CDATA[Oncology]]></dc:subject>
<dc:title><![CDATA[Ovarian cancer: What is the new drug approved for the NHS in England?]]></dc:title>
<prism:publicationDate>2026-06-05</prism:publicationDate>
<prism:section>News</prism:section>
<prism:volume>393</prism:volume>
<prism:issueIdentifier>jun05_1</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/393/bmj-2025-088686.short?rss=1">
<title><![CDATA[Systematic estimates of global causes of neonatal and under 5 mortality in 2000-24: secondary data analysis using bayesian multinomial logistic regression]]></title>
<link>http://www.bmj.com/content/393/bmj-2025-088686.short?rss=1</link>
<description><![CDATA[AbstractObjectiveTo estimate cause specific mortality among neonates and children under 5 for 195 countries from 2000 to 2024.DesignSecondary data analysis using a Bayesian multinomial logistic regression model to estimate cause specific mortality fractions.Data sourcesPubMed, Embase, Web of Science, SCOPUS, Cochrane, Global Health Index Medicus, PAHO, Global Health OVID, Africa-Wide Information, IndMed, WHO Mortality Database, Demographic and Health Surveys (DHS), Multiple Indicator Cluster Surveys (MICS), and Health and Demographic and Surveillance Systems (HDSS).Inclusion criteriaStudies in the general population reporting empirical cause specific mortality for at least two causes in the age groups of interest, with a specified method for cause ascertainment. For studies identifying causes of mortality with verbal autopsy, ≥25 deaths reported with ≤25% of these deaths with unknown cause. For vital registration, ≥80% population completeness and ≤10% deaths assigned to ill defined causes determined by the international classification of diseases, 10th revision.ResultsCause specific mortality for countries with adequate quality vital registration was estimated with their own data with minor adjustments. For countries with low mortality without adequate quality vital registration, cause specific mortality was modeled by age group and based on vital registration. For high mortality areas, cause specific mortality was modeled primarily on the basis of verbal autopsy data identified in a systematic review. Estimated cause distributions were applied to all cause mortality rates and death counts estimated by the United Nations Inter-agency Group for Child Mortality Estimation. Among 4.9 million estimated global deaths in under 5s in 2024, the most important cause of death was preterm birth complications, with 0.82 (90% uncertainty interval 0.76 to 0.88) million deaths and 6.17 (5.93 to 6.42) deaths for every 1000 live births. This was followed closely by lower respiratory infections at 0.66 (0.60 to 0.71) million deaths, intrapartum related events (0.48 (0.43 to 0.52) million), and malaria (0.45 (0.39 to 0.51) million). Analysis for trends over time showed that the decline in most causes has slowed since 2016.ConclusionWith the recent slowed pace of decline in under 5 mortality for most primary causes of death, many high mortality countries are at risk of missing the sustainable development goal targets of ≤12 neonatal deaths and ≤25 under 5 deaths per 1000 live births without acceleration. Estimates presented here can help countries to determine the most appropriate course of action to reduce under 5 mortality and achieve these targets.]]></description>
<dc:creator><![CDATA[Jamie Perin, David Prieto-Merino, Astha Wahi, Sandipan Pramanik, Hallie Eilerts-Spinelli, Francisco Villavicencio, Tyler H McCormick, Danzhen You, Abhirup Datta, Kathleen L Strong, Robert E Black, Li Liu]]></dc:creator>
<dc:date>2026-06-04T08:45:59-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2025-088686</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2025-088686</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Systematic estimates of global causes of neonatal and under 5 mortality in 2000-24: secondary data analysis using bayesian multinomial logistic regression]]></dc:title>
<prism:publicationDate>2026-06-04</prism:publicationDate>
<prism:section>Research</prism:section>
<prism:volume>393</prism:volume>
<prism:issueIdentifier>jun04_10</prism:issueIdentifier>
</item>
<item rdf:about="http://www.bmj.com/content/393/bmj-2026-715244.short?rss=1">
<title><![CDATA[Global estimates of mortality in newborn babies, children, and adolescents]]></title>
<link>http://www.bmj.com/content/393/bmj-2026-715244.short?rss=1</link>
<description><![CDATA[While the growth rate of the world's population has declined to 0.86% per year, the rate of mortality has also slowed down. Part of the decline in mortality can be attributed to considerable efforts on young infant and child survival, which have been successful. But the message from a linked series of papers on neonatal, child, and adolescent mortality published in The BMJ (doi:10.1136/bmj-2025-088684; doi:10.1136/bmj-2025-088685; doi:10.1136/bmj-2025-088686; doi:10.1136/bmj-2025-088687) is clear: since 2015, the rate of decline in mortality rates in newborn babies, children under 5 years old, older children, and adolescents has slowed substantially.1234 Although the number of deaths among children under 5 has decreased over the past two decades, 4.9 million children in this age group died in 2024, with almost half of the deaths occurring in newborn babies. While the mortality rate among children under 5 declined by 3.9% in 2000-15, the rate of decline was only 1.5% in...]]></description>
<dc:creator><![CDATA[Tahmeed Ahmed, Fred Binka, Buddha Basnyat]]></dc:creator>
<dc:date>2026-06-04T08:46:29-07:00</dc:date>
<dc:identifier>info:doi/10.1136/bmj-2026-715244</dc:identifier>
<dc:identifier>hwp:master-id:bmj;bmj-2026-715244</dc:identifier>
<dc:publisher>BMJ Publishing Group Ltd</dc:publisher>
<dc:title><![CDATA[Global estimates of mortality in newborn babies, children, and adolescents]]></dc:title>
<prism:publicationDate>2026-06-04</prism:publicationDate>
<prism:section>Editorials</prism:section>
<prism:subsection1>Editorial</prism:subsection1>
<prism:volume>393</prism:volume>
<prism:issueIdentifier>jun04_9</prism:issueIdentifier>
</item>
</rdf:RDF>